Ertapenem (MK-0826) 是一种广谱的长效 β-内酰胺抗生素。Ertapenem 对多种厌氧菌具有广谱抗菌活性，其MIC值为 0.12 μg/mL。Ertapenem 可用于皮肤、肺、胃、骨盆和泌尿道的细菌感染相关的研究。
| 生物活性 | Ertapenem (MK-0826) is a broad spectrum and long acting β-lactamantibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a modeMICof 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract[1][2]. |
| IC50& Target | |
体外研究
(In Vitro) | Ertapenem (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively[1].
Cell Viability Assay[1] | Cell Line: | B. fragilis(ATCC 25285),B. thetaiotaomicron(ATCC 29741), andEubacterium lentum(ATCC 43055) | | Concentration: | 0-100 μg/mL approximately | | Incubation Time: | 48 h | | Result: | Inhibited 99.1% of all isolate with a mode MIC of 0.12 μg/mL and MIC90of 1 μg/mL, and 98.8% of the isolates were susceptible among the B. fragilis group. |
|
体内研究
(In Vivo) | Ertapenem (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection,S. aureusthigh tissue infection model) shows >3 log10CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10CFU eliminated at 2 mg/kg[2].Ertapenem (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of<0.25 mg/kg/dose[2].
| Animal Model: | S. aureusthigh tissue infection model (DBA/2 mice)[2] | | Dosage: | 0.5,1, 2, 5, 10 mg/kg (given at 2, 6, 10, 24, 48, 72, 96, 120 h) | | Administration: | Subcutaneous injection (0.5 mL after infection) | | Result: | Displayed >3 log10CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg.Maintained the activity with 3.3 and 4.4 log10CFU eliminated at 2 mg/kg. |
| Animal Model: | Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)[2] | | Dosage: | 0-3 mg/kg approximately | | Administration: | Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection) | | Result: | Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of<0.25 mg/kg/dose. |
| Animal Model: | CD-1 mice, rats[2] | | Dosage: | 10 mg/kg approximately | | Administration: | Intraperitoneal injection (pharmacokinetic assay) | | Result: | Exhibited an AUC0-∞ranging from 1.8-21.82 μgohr/mL in tissue in mice following a 10-mg/kg i.p. dose.Exhibited slow clearance rate with a t1/2βof 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8of 284.15μgohr/mL. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com